ASH 2019 Post Wrap-Up
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs.
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features.
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations
For patients with chronic lymphocytic leukemia who are treated with acalabrutinib, disease progression is largely attributed to specific mutations in Bruton tyrosine kinase (BTK). Acalabrutinib resistance mechanisms are similar to those seen with ibrutinib.
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL).
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia.
Results 1 - 10 of 10